Dagenais GR, et al. - In this study of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial including 12,090 people with dysglycemia who were at high risk of cardiovascular diseases (CVD), had an ankle-brachial index either greater than 0.9 or 0.9 or less, and followed for 6.2 years, researchers determined the if insulin glargine or omega-3 supplements have any impact on the incidence and progression of peripheral artery disease (PAD). They randomized patients who had dysglycemia and cardiovascular risk factors to titrated insulin glargine vs standard care, and to either 1 g of omega-3 per day or placebo. Investigators found that neither insulin glargine nor 1 g omega-3 supplements had any significant impact on the incidence or progression of PAD in patients with diabetes of short duration, with prediabetes, with good glycemic control, and who are at high risk of CVD.